| Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy. | |
| | |
MedLine Citation:
|
PMID: 10219465 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The therapeutic effectiveness of a benfotiamine (CAS 22457-89-2)-vitamin B combination (Milgamma-N), administered in high (4 x 2 capsules/day, = 320 mg benfotiamine/day) and medium doses (3 x 1 capsules/day), was compared to a monotherapy with benfotiamine (Benfogamma) (3 x 1 tablets/day, = 150 mg benfotiamine/day) in diabetic patients suffering from painful peripheral diabetic neuropathy (DNP). In a 6-week open clinical trial, 36 patients (aged 40 to 70 yrs) having acceptable metabolic control (HbA1c < 8.0%) were randomly assigned to three groups, each of them comprising 12 participants. Neuropathy was assessed by five parameters: the pain sensation (evaluated by a modified analogue visual scale), the vibration sensation (measured with a tuning fork using the Riedel-Seyfert method) and the current perception threshold (CPT) on the peroneal nerve at 3 frequencies: 5, 250 and 2000 Hz). Parameters were registered at the beginning of the study and at the end of the 3rd and 6th week of therapy. An overall bneneficial therapeutic effect on the neuropathy status was observed in all three groups during the study, and a significant improvement in most of the parameters studied appeared already at the 3rd week of therapy (p < 0.01). The greatest change occurred in the group of patients receiving the high dose of benfotiamine (p < 0.01 and 0.05, resp., compared to the othr groups). Metabolic control did not change over the study. It is concluded that benfotiamine is most effective in large doses, although even in smaller daily dosages, either in combination or in monotherapy, it is effective. |
| | |
Authors:
|
G Winkler; B Pál; E Nagybéganyi; I Ory; M Porochnavec; P Kempler |
Related Documents
:
|
11406335 - Analgesic profile of peroral and topical ketoprofen upon low ph-induced muscle pain. 17666715 - Remifentanil patient-controlled analgesia for labour: optimizing drug delivery regimens. 3366035 - Effects of ibuprofen on postoperative bowel motility and propulsion. 9197945 - Antinociceptive effects of the kappa-opioid receptor agonist rp 60180 compared with pen... 4038975 - Measurements of radiation dose distributions for shielded cervical applicators. 1721975 - Features of the acute hypotensive action of carvedilol and its ameliorating effect on m... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Arzneimittel-Forschung Volume: 49 ISSN: 0004-4172 ISO Abbreviation: Arzneimittelforschung Publication Date: 1999 Mar |
Date Detail:
|
Created Date: 1999-06-07 Completed Date: 1999-06-07 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 0372660 Medline TA: Arzneimittelforschung Country: GERMANY |
Other Details:
|
Languages: eng Pagination: 220-4 Citation Subset: IM |
Affiliation:
|
2nd Department of Internal Medicine, Municipal St. John's Hospital, Budapest, Hungary. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Blood Glucose / metabolism Chelating Agents / administration & dosage*, therapeutic use* Cholesterol / blood Diabetic Neuropathies / complications, drug therapy* Female Hemoglobin A, Glycosylated / metabolism Humans Male Middle Aged Pain / drug therapy*, etiology Pain Measurement Pain Threshold / drug effects Thiamine / administration & dosage, analogs & derivatives*, therapeutic use Triglycerides / blood |
| Chemical | |
Reg. No./Substance:
|
0/Blood Glucose; 0/Chelating Agents; 0/Hemoglobin A, Glycosylated; 0/Triglycerides; 22457-89-2/benphothiamine; 57-88-5/Cholesterol; 59-43-8/Thiamine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hemodynamics and mitochondrial energy metabolism in right heart hypertrophy after acute hypoxic stre...
Next Document: Pharmacokinetics of latanoprost in the cynomolgus monkey. 1st communication: single intravenous, ora...